Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Triplex Pharmaceutical Corp. other research news

Triplex Pharmaceutical Corp.
Triplex received $140,000 from three Phase I SBIR

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE